Nanolek is a biopharmaceutical company; most of its drugs are innovative by one of the following criteria: by technology of their production, by composition and principle of action, and by representation on the Russian market.

The company is engaged in research and development in cooperation with leading Russian research institutes and foreign research companies. Some of the company's developments are co-financed by the state under the Federal Target Program "Pharma 2020" as the developments of strategically important drugs.

Innovative drugs produced by Nanolek focus primarily on consumers and have common characteristic advantages:

  • Low probability of side effects due to the use of toxicity reducing technologies
  • High therapeutic activity through the use of sustained-release technologies (nanocontainers)
  • Availability and high quality due to local production in accordance with the GMP standards and the use of modern pharmaceutical technologies